{
    "Clinical Trial ID": "NCT00003830",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm I:Sentinel Node Resection+Conventional Axillary Dissection",
        "  Sentinel node resection immediately followed by axillary dissection",
        "  conventional surgery: Sentinel node resection immediately followed by axillary dissection.",
        "INTERVENTION 2: ",
        "  Arm II: Sentinel Node Resection Followed by Node Examination",
        "  Sentinel node resection followed by node examination then axillary dissection if positive sentinel node.",
        "  Sentinel node resection followed by node examination: Sentinel node resection followed by node examination then axillary dissection if positive sentinel node. No axillary dissection for negative sentinel node."
    ],
    "Eligibility": [
        "DISEASE CHARACTERISTICS:",
        "  Resectable invasive adenocarcinoma of the breast, confirmed by 1 of the following:",
        "  Histologically confirmed by core or open biopsy",
        "  Confirmed by fine needle aspiration cytology AND positive clinical breast examination and ultrasound or mammography",
        "  Clinically negative lymph nodes",
        "  No positive ipsilateral axillary lymph nodes",
        "  No prior removal of ipsilateral axillary lymph nodes",
        "  No suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes, unless proven nonmalignant by biopsy",
        "  No ulceration, erythema, infiltration of the skin or underlying chest wall (complete fixation), peau d'orange, or skin edema of any magnitude",
        "  Tethering or dimpling of the skin or nipple inversion allowed",
        "  No bilateral malignancy or mass in the opposite breast that is suspicious for malignancy, unless proven nonmalignant by biopsy",
        "  No diffuse tumors or multiple malignant tumors in different quadrants of the breast",
        "  No other prior breast malignancy except lobular carcinoma in situ",
        "  No prior or concurrent breast implants",
        "  Hormone receptor status:",
        "  Not specified",
        "  PATIENT CHARACTERISTICS:",
        "  Age:",
        "  18 years and older",
        "  Sex:",
        "  Female",
        "  Menopausal status:",
        "  Not specified",
        "Performance status:",
        "  Not specified",
        "  Life expectancy:",
        "  At least 10 years (excluding diagnosis of cancer)",
        "  Hematopoietic:",
        "  Not specified",
        "  Hepatic:",
        "  No hepatic systemic disease",
        "  Renal:",
        "  No renal systemic disease",
        "  Cardiovascular:",
        "  No cardiovascular systemic disease",
        "  Other:",
        "  No prior malignancy within past 5 years except:",
        "  Effectively treated squamous cell or basal cell skin cancer",
        "  Surgically treated carcinoma in situ of the cervix",
        "  Surgically treated lobular carcinoma in situ of the ipsilateral or contralateral breast",
        "  No concurrent psychiatric or addictive disorder",
        "  PRIOR CONCURRENT THERAPY:",
        "  Biologic therapy:",
        "  No prior immunotherapy for this cancer",
        "  Chemotherapy:",
        "  No prior chemotherapy for this cancer, including neoadjuvant chemotherapy",
        "  Endocrine therapy:",
        "  No prior hormonal therapy for this cancer",
        "  Radiotherapy:",
        "  No prior radiotherapy for this cancer",
        "  Surgery:",
        "  See Disease Characteristics",
        "  No prior breast reduction surgery",
        "  Prior excisional biopsy or lumpectomy allowed"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Morbidity - Number of Participants With Residual Shoulder Abduction Deficit",
        "  Morbidity as measured by residual shoulder abduction deficit. Shoulder Abduction Deficit definition: Shoulder range of motion decreased by greater than or equal to 10% as compared with that measured prior to surgery.",
        "  Time frame: Before and after surgery (within 30 days of randomization)",
        "Results 1: ",
        "  Arm/Group Title: Arm I:Sentinel Node Resection+Conventional Axillary Dissection",
        "  Arm/Group Description: Sentinel node resection immediately followed by axillary dissection",
        "  conventional surgery: Sentinel node resection immediately followed by axillary dissection.",
        "  Overall Number of Participants Analyzed: 1449",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  276  19.0%",
        "Results 2: ",
        "  Arm/Group Title: Arm II: Sentinel Node Resection Followed by Node Examination",
        "  Arm/Group Description: Sentinel node resection followed by node examination then axillary dissection if positive sentinel node.",
        "  Sentinel node resection followed by node examination: Sentinel node resection followed by node examination then axillary dissection if positive sentinel node. No axillary dissection for negative sentinel node.",
        "  Overall Number of Participants Analyzed: 1519",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  200  13.2%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 9/2788 (0.32%)",
        "  Anaphylaxis 5/2788 (0.18%)",
        "  Infections and infestations - Other, specify 2/2788 (0.07%)",
        "  Nervous system disorders - Other, specify 0/2788 (0.00%)",
        "  Respiratory, thoracic and mediastinal disorders - Other, specify 1/2788 (0.04%)",
        "  Thromboembolic event 1/2788 (0.04%)",
        "Adverse Events 2:",
        "  Total: 8/2800 (0.29%)",
        "  Anaphylaxis 5/2800 (0.18%)",
        "  Infections and infestations - Other, specify 0/2800 (0.00%)",
        "  Nervous system disorders - Other, specify 1/2800 (0.04%)",
        "  Respiratory, thoracic and mediastinal disorders - Other, specify 1/2800 (0.04%)",
        "  Thromboembolic event 2/2800 (0.07%)"
    ]
}